Logo American Journal of Case Reports

Call: 1.631.629.4328
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo American Journal of Case Reports Logo American Journal of Case Reports Logo American Journal of Case Reports

09 September 2021: Articles  Saudi Arabia

Giant Cell Carcinoma of the Endometrium: A Case Report of a Rare Entity with Aggressive Behavior

Challenging differential diagnosis, Rare disease

Maria Arafah1ABEF*, Raghad Adnan Bokhari1ABEF, Khalid Akkour2BCD, Emadeddin Raddaoui3AEF

DOI: 10.12659/AJCR.932916

Am J Case Rep 2021; 22:e932916



BACKGROUND: Giant cell carcinoma of the endometrium is one of the rare variants of endometrial carcinoma, with a very limited number of reported cases and limited follow-up data. The purpose of this case report is to present yet another example of endometrial giant cell carcinoma, discuss its differential diagnosis and management course, and review all previously reported cases.

CASE REPORT: We report a case of a 71-year-old woman who presented with vaginal bleeding. Her laboratory investigations were within normal limits except for her glycated hemoglobin, which was 10%. Ultrasound and computed tomography scans showed an endometrial mass invading the myometrium. Microscopically, the tumor is comprised almost exclusively of multinucleated giant cells. The patient underwent a total robotic hysterectomy with bilateral salpingo-oophorectomy and lymph nodes dissection, and she is currently undergoing adjuvant radiotherapy.

CONCLUSIONS: Giant cell carcinoma of the endometrium is a rare diagnosis that can be established by histopathological examination after excluding the other common giant cell-rich lesions that may occur in the endometrium.

Keywords: Carcinoma, Giant Cell, Endometrium, Endometrial Neoplasms, Female, Humans, Hysterectomy, Ultrasonography


Endometrial carcinoma is the sixth most frequently diagnosed cancer in women and the second most common carcinoma of the female genital tract, with an estimated 66 570 new cases and 12 940 deaths in 2021 [1,2]. The current World Health Organization (WHO) classification of tumors of the uterine corpus includes the common types of endometrial carcinoma; however, a few other rare variants have been reported in the literature, like hepatoid carcinoma, glassy cell carcinoma, lymphoepithelioma-like carcinoma, adenocarcinoma with trophoblastic differentiation, and giant cell carcinoma (GCC) [2,3]. Giant cell carcinoma of the endometrium was first described in 1991 by Jones et al, with only 15 cases reported in the literature [4–9]. Herein, we present a case of GCC of the endometrium in a 71-year-old woman. We also review the previously reported cases and discuss the various features of this infrequently reported variant, emphasizing its differential diagnosis and the importance of recognizing this entity to avoid misdiagnosis or improper management.

Case Report

A 71-year-old postmenopausal woman presented with vaginal bleeding. She had a history of diabetes, hypertension, hypothyroidism, and aortic valve stenosis. Her surgical history included a sleeve gastrectomy and a discectomy. Pelvic examination was unremarkable, with no palpable lymph nodes. Her cervical smear was negative; however, an endometrial biopsy showed a high-grade carcinoma with bizarre and multinucleated giant cells. The patient was admitted for further investigations, and her laboratory tests were within normal limits, including tumor markers (CA-125, CA15-3, CA19.9, AFP, and CEA). Her glycated hemoglobin level (HbA1c) was 10%. Transvaginal ultrasound showed a thickened endometrium (17 mm) with some cystic areas and average-sized uterus and adnexa. A computed tomography scan of the chest, abdomen, and pelvis showed an endometrial mass involving more than 50% of the myometrial thickness, without evidence of extension beyond the serosa. There was no evidence of invasion into the adjacent structures, hydronephrosis, or distant metastasis.

The patient underwent a total robotic hysterectomy with bilateral salpingo-oophorectomy and pelvic lymph nodes sampling. The para-aortic lymph nodes were not dissected. Macroscopically, a tan friable mass measuring 2.5×2.0×2.0 cm was seen within the endometrial cavity and invading into the inner half of the myometrium. The cervix, ovaries, and fallopian tubes were grossly unremarkable. Microscopically, the tumor comprised sheets of multinucleated giant cells with abundant dense eosinophilic cytoplasm, marked nuclear pleomorphism, prominent nucleoli, and numerous atypical mitoses (Figure 1). The giant cells comprised around 95% of the tumor volume, with no evidence of other conventional types of endometrial carcinoma. The remainder of the neoplasm showed undifferentiated carcinoma (Figure 2). The tumor infiltrated into the inner half of the myometrium, with no evidence of lymphovascular invasion or cervical involvement. The adnexa were unremarkable, and a total of 4 lymph nodes were negative for meta-static carcinoma.

A panel of immunohistochemical stains was done and showed tumor cells positivity for vimentin, CAM 5.2 (Figure 3), p16 (Figure 4), and cytokeratin 7 (CK 7). p53 showed a wild-type pattern of staining. Tumor cells were negative for estrogen receptor (ER), desmin, myogenin, β-human chorionic gonadotropin (β-hCG), and CD68. In addition, they showed intact nuclear staining for mismatch repair proteins (MLH1, MSH2, MSH6, and PMS2). The diagnosis rendered was a giant cell carcinoma of the endometrium, International Federation of Gynecology and Obstetrics (FIGO) stage IA. Upon the consensus of a multidisciplinary tumor board, the patient is currently undergoing adjuvant radiotherapy. A written informed consent for patient information and images to be published was obtained from the patient.


Giant cell carcinoma of the endometrium is a rare variant of endometrial carcinoma first reported in 1991 by Jones et al [4]. The defining microscopic feature is the presence of bizarre multinucleated and tumor giant cells accounting for a substantial part of the tumor. The remainder of the tumor usually shows mononuclear undifferentiated carcinoma or a more conventional type of endometrial carcinoma [4]. This entity has not been recognized yet by the WHO as a separate variant of endometrial carcinoma; thus, the exact percentage of giant cells within an endometrial carcinoma qualifying for this diagnosis remains subjective. Nonetheless, the WHO states that any percentage of high-grade carcinoma is sufficient to label the tumor a mixed endometrial carcinoma [2]. Two cases in the original series by Jones et al had a minor giant cell component (15%), one of which presented with advanced disease (FIGO IIIC2) [4]. Similarly, one case in the series reported by Mulligan et al had a 30% giant cell component, and the patient also presented with extrauterine disease [6]. Hence, given the aggressive behavior of endometrial carcinomas containing giant cells, cases with a minor giant cell component are better classified as mixed endometrial carcinomas in agreement with the WHO classification [2,4,6].

Giant cell carcinoma should be differentiated from other endometrial tumors, which may have a prominent giant cell component, including trophoblastic tumors, carcinosarcoma, or primary sarcomas. In uterine choriocarcinoma or endometrial carcinoma with choriocarcinomatous differentiation, patients present with elevated serum β-hCG levels. The multinucleated cells in these tumors are either of a trophoblastic origin or demonstrating trophoblastic immunomorphological features depicted by the positivity of tumor cells to β-hCG [10]. Uterine carcinosarcoma is a biphasic tumor composed of sharply juxtaposed carcinomatous and sarcomatous components [2]. Leiomyosarcoma is a malignant smooth muscle tumor composed of intersecting fascicles of spindle cells with eosinophilic cytoplasm, which may also contain multinucleated giant cells; however, these cells are positive for smooth muscle markers, including desmin, smooth muscle actin (SMA), and h-caldesmon and they are negative for cytokeratin and β-hCG.

Giant cell carcinoma of the endometrium has been reported in 16 cases (including ours) to date (Table 1) [4–9]. The mean age of the patients was 66 years (range=43 to 83 years), and most of them presented with vaginal bleeding. The giant cell component was admixed with another type of endometrial carcinoma in most cases, including endometrioid adenocarcinoma, serous carcinoma, and clear cell carcinoma (Table 1). In our case and one of the cases reported by Mulligan et al, the tumor was almost exclusively composed of tumor giant cells [6]. Tumor cells were highlighted with cytokeratins (pan-CK, CK AE1/AE3, and CAM5.2) in all cases, and in some, they were also positive for vimentin and ER. When they were performed, β-hCG, CD68, p63, desmin, SMA, and MyoD1 were negative in tumor cells. Most of the reported cases were FIGO stage I, 1 case was stage II, 3 cases were stage III, and 2 cases were stage IV with limited follow-up data (Table 1). The management varied among patients; for example, in the cases reported by Bhattacharyya et al [7] and Sharma et al [8], patients underwent a total hysterectomy and bilateral salpingo-oophorectomy, and their follow-ups were uneventful. In the case reported by Ayık Aydın et al [9], the patient underwent a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and bilateral pelvic and para-aortic lymphadenectomy. Although hormonal therapy is a well-documented treatment modality for primary, metastatic, and recurrent cases of endometrial carcinoma, its role in endometrial GCC remains unknown [9].

Information regarding tumor behavior and long-term prognosis is limited. In the original series, 4 patients had tumors with deep myometrial invasion, and they all developed recurrence, and 3 died of disease within 3 years [4]. In another series, 2 patients with a tumor confined to the uterus and extensive lymphovascular invasion developed lung metastasis 4 years after the initial diagnosis [6]. On the other hand, 2 patients, 1 in each of the series mentioned above, had stage 1 disease and remained disease-free at 6 and 14 years of follow-up, respectively [4,6]. Consequently, the prognosis of GCC is still undetermined even though it showed aggressive behavior in some instances.

The clinical differences between endometrial GCC and the other more common types of endometrial carcinoma, the appropriate therapeutic approach for endometrial GCC, and its prognosis are still controversial. Therefore, more cases should be collected and studied to highlight the significance of this variant further.


Giant cell carcinoma of the endometrium is a rare diagnosis with a small number of reported cases and limited data on its long-term prognosis. Nevertheless, pathologists should be aware and recognize this variant after excluding other common giant cell-rich lesions to avoid misdiagnosis and improper management.


1.. : SEER Cancer Stat Facts: Uterine Cancer, 2020, Bethesda, National Cancer Institute SEER Cancer Stat Facts: Uterine Cancer. National Cancer Institute. Bethesda, MD. Available at: https://seer.cancer.gov/statfacts/html/corp.html

2.. : Volume 4: Female Genital Tumours, in: WHO Classification of Tumours, 2020, Geneva, IARC (International Agency for Research on Cancer)

3.. Rutgers JK, Update on pathology, staging, and molecular pathology of endometrial (uterine corpus) adenocarcinoma: Future Oncol, 2015; 11(23); 3207-18

4.. Jones MA, Young RH, Scully RE, Endometrial adenocarcinoma with a component of giant cell carcinoma: Int J Gynecol Pathol, 1991; 10(3); 260-70

5.. Mardi K, Sharma M, Giant cell carcinoma of the endometrium: Internet J Gynecol Obstet [online], 2008; 12(1); 4545 Available from: https://ispub.com/IJGO/12/1/4545

6.. Mulligan AM, Plotkin A, Rouzbahman M, Endometrial giant cell carcinoma: A case series and review of the spectrum of endometrial neoplasms containing giant cells: Am J Surg Pathol, 2010; 34(8); 1132-38

7.. Bhattacharyya A, Gon S, Bandyopadhyay G, Giant cell carcinoma of endometrium: A rare clinical entity: Iran J Pathol, 2012; 7(3); 197-202

8.. Sharma P, Ahluwalia C, Kolte S, Mandal AK, Giant cell carcinoma of endometrium: A rare case report and review of literature: Clin Cancer Investig J, 2016; 5(1); 79-82

9.. Ayık Aydın H, Tuncer HA, Erdoğan G, Şimşek T, Uterine giant cell carcinoma: A case report and review of the literature: Turk J Obstet Gynecol, 2019; 16(1); 76-79

10.. Yamada T, Mori H, Kanemura M, Endometrial carcinoma with choriocarcinomatous differentiation: A case report and review of the literature: Gynecol Oncol, 2009; 113(2); 291-94

In Press

Case report  Brazil

Successful Case of Double Valve Replacement Surgery Using Autologous Blood Transfusion: A Patient's Autonom...

Am J Case Rep In Press; DOI: 10.12659/AJCR.943675  


Case report  Saudi Arabia

Pancreatitis with Intraabdominal Venous Thrombosis as an Initial Presentation of Parathyroid Adenoma: A Rar...

Am J Case Rep In Press; DOI: 10.12659/AJCR.943838  


Case report  Singapore

Delayed-Onset Hypnopompic Visual Hallucinations 20 Years After Initiation of Propranolol Therapy for System...

Am J Case Rep In Press; DOI: 10.12659/AJCR.944342  

Case report  China (mainland)

Odontogenic Keratocyst in Maxillary Sinus with Ectopic Third Molar: A Case Report

Am J Case Rep In Press; DOI: 10.12659/AJCR.944543  

Most Viewed Current Articles

07 Mar 2024 : Case report  USA 39,654

Neurocysticercosis Presenting as Migraine in the United States

DOI :10.12659/AJCR.943133

Am J Case Rep 2024; 25:e943133


10 Jan 2022 : Case report  Germany 31,349

A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV...

DOI :10.12659/AJCR.935263

Am J Case Rep 2022; 23:e935263

23 Feb 2022 : Case report  USA 18,313

Penile Necrosis Associated with Local Intravenous Injection of Cocaine

DOI :10.12659/AJCR.935250

Am J Case Rep 2022; 23:e935250

19 Jul 2022 : Case report  Saudi Arabia 18,005

Atlantoaxial Subluxation Secondary to SARS-CoV-2 Infection: A Rare Orthopedic Complication from COVID-19

DOI :10.12659/AJCR.936128

Am J Case Rep 2022; 23:e936128

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

American Journal of Case Reports eISSN: 1941-5923
American Journal of Case Reports eISSN: 1941-5923